In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash
Journal of the European Academy of Dermatology and Venereology · 2025-08 · 39 (8)
DOI: 10.1111/jdv.20719 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 06.05.2025. Verfasst von Azael Freites-Martinez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Autor:innen und Institutionen
- Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain.
- First Department of Dermatology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Oncodermatology Department, Cancer University Institute, Toulouse Oncopole, Toulouse, France.
ORCID-Profile: Azael Freites-Martinez, Zoe Apalla, Vincent Sibaud
Zitieren
APA
Freites-Martinez, A., Apalla, Z., & Sibaud, V. (2025). In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash. Journal of the European Academy of Dermatology and Venereology, 39(8). https://doi.org/10.1111/jdv.20719
Vancouver
Freites-Martinez A, Apalla Z, Sibaud V. In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash. Journal of the European Academy of Dermatology and Venereology. 2025;39(8). doi:10.1111/jdv.20719
BibTeX
@article{FreitesMartinez2025,
author = {Freites-Martinez, Azael and Apalla, Zoe and Sibaud, Vincent},
title = {In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {8},
doi = {10.1111/jdv.20719}
}
EUVIMED